Kaplan–Meier analyses revealed that mice bearing IL30-TRAMP-C1 tumors and treated with Cas9mIL30-mPSCA NxPs survived longer (92 days) than controls (PBS- and empty-mPSCA-treated) (64 days) and PBS-treated TRAMP-C1 tumor-bearing mice (78 days) (log-rank test: p < 0.000001) (Fig. 8k). The gene discussed is IL27; the disease is neoplasm.